 |
| Preimplantation Genetic Diagnosis Market |
The global Preimplantation Genetic Diagnosis Market is estimated to be valued at US$ 64.08 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preimplantation genetic diagnosis (PGD) is a medical procedure that involves
testing embryos for genetic diseases before implantation and pregnancy. It
allows identification of genetic defects in embryos created through in vitro
fertilization (IVF) to select unaffected embryos for implantation. PGD is
useful for couples with a family history of genetic disorders or chromosomal
abnormalities in order to have healthier children.
Market key trends:
One of the key trends fueling the growth of preimplantation genetic diagnosis
market is the increasing use of PGD for multiple genetic assessments in a
single IVF cycle. Traditionally, PGD was used to test for a single genetic
condition. However, with advancement in technologies like next-generation
sequencing, multiple genetic tests can now be performed during a single IVF
cycle. This has increased the efficiency and affordability of PGD procedures.
Moreover, the advent of technologies like array comparative genomic
hybridization has enabled comprehensive screening of entire genomes of embryos
for abnormalities. This is helping to identify more genetic defects.
Segment Analysis
The preimplantation genetic diagnosis market is segmented based on application,
technology, end-user and region. By application, the aneuploidy screening
segment held the largest market share in 2022 owing to increasing prevalence of
aneuploidy defects such as Down syndrome during IVF. By technology, the next
generation sequencing (NGS) segment is dominating the market due to rise in
affordability and accuracy of NGS over other technologies. By end user,
fertility clinics are dominating the market as these clinics perform majority
of IVF cycles and PGD tests.
Key Takeaways
The global Preimplantation
Genetic Diagnosis Market Growth is expected to witness high growth,
exhibiting CAGR of 6.2% over the
forecast period, due to increasing incidence of genetic abnormalities and
growth in popularity of IVF treatment.
Regionally, North America currently dominates the PGD market owing to high
adoption of advanced reproductive technologies and presence of major market
players in the region. Asia Pacific region is expected to grow at the fastest
pace during the forecast period due to rising fertility tourism, increasing
healthcare expenditures and growing medical tourism industry.
The global preimplantation genetic diagnosis market size is projected to reach
US$ 64.08 Mn in 2023. Key players operating in the preimplantation genetic
diagnosis market are Amgen, Quest Diagnostics, Genentech Inc., Vertex,
PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., and
Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina,
Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc.,
Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.
Read More
0 Comments